Llama Antibody, Rotavirus Diarrhoea, Children

PHASE2CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

November 30, 2009

Conditions
Male Children6-24 Months Old With Rotaviral DiarrhoeaNon-cholera Patients
Interventions
DRUG

VHH batch 203027

The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.

DRUG

Placebo product

The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.

Trial Locations (1)

1212

Dhaka Hospital, Dhaka

All Listed Sponsors
collaborator

Unilever Nederland Holdings

UNKNOWN

lead

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

NCT01259765 - Llama Antibody, Rotavirus Diarrhoea, Children | Biotech Hunter | Biotech Hunter